quinuclidines has been researched along with Hematologic Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul Rahman, MHFB; Abdullah, MM; Ahmad Annuar, MA; Ahmad Badruddin, RBA; Chong, KJ; Lai, CNB; Lam, KS; Lau, KL; Low, JSH; Md Yusof, M; Ng, SC; Nonis, JG; Yap, BK | 1 |
| Bai, LY; Chiu, CF; Hsieh, CY; Liao, YM; Lin, CC; Lin, CY; Lin, PH; Lo, WC; Yeh, SP | 1 |
| Andersson, PO; Cherif, H; Deneberg, S; Juliusson, G; Lazarevic, V; Lehmann, S; von Euler, M | 1 |
| Bianchini, C; Bonanno, V; Crescimanno, A; Musso, M; Perrone, T; Polizzi, V; Porretto, F; Scalone, R | 1 |
| Balu, S; Buchner, D; Craver, C; Gayle, J | 1 |
| Azevedo, W; Jacobs, P; Matsouka, P; Pinto, A; Schwartzberg, LS | 1 |
| Ali, D; Andersson, PO; Andrén, O; Bykov, VJ; Cherif, H; Juliusson, G; Lehmann, S; Moshfegh, A; Paul, C; Tidefelt, U; Uggla, B; Wiman, KG; Yachnin, J | 1 |
1 review(s) available for quinuclidines and Hematologic Neoplasms
| Article | Year |
|---|---|
The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
Topics: Antiemetics; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Half-Life; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Salvage Therapy; Serotonin 5-HT3 Receptor Antagonists; Stem Cell Transplantation; Transplantation Conditioning; Vomiting | 2012 |
3 trial(s) available for quinuclidines and Hematologic Neoplasms
| Article | Year |
|---|---|
Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Middle Aged; Nausea; Palonosetron; Quinuclidines; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vomiting; Young Adult | 2014 |
An open-label phase I dose-finding study of APR-246 in hematological malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinuclidines; Treatment Outcome | 2016 |
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Hormonal; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Hematologic Neoplasms; Humans; Isoquinolines; Italy; Male; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2009 |
3 other study(ies) available for quinuclidines and Hematologic Neoplasms
| Article | Year |
|---|---|
Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Benzeneacetamides; Dexamethasone; Hematologic Neoplasms; Humans; Nausea; Palonosetron; Piperazines; Pyridines; Quinuclidines; Vomiting | 2022 |
Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Nausea; Outpatients; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; United States; Vomiting; Young Adult | 2011 |
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genes, p53; Hematologic Neoplasms; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Patient Safety; Pharmacogenetics; Prospective Studies; Prostatic Neoplasms; Quinuclidines; Risk Factors; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2012 |